Name | HDAC-IN-57 |
---|
Description | HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC50s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC50 of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity[1]. |
---|---|
Related Catalog | |
Target |
HDAC1:2.07 nM (IC50) HDAC2:4.71 nM (IC50) HDAC6:2.4 nM (IC50) HDAC8:107 nM (IC50) |
In Vitro | HDAC-IN-57 (Compound 5e) (1.0 μM,2.5 μM,5.0 μΜ; 48 小时) 抑制实体肿瘤细胞系 MGC-803,A549,HCT-116 的迁移和侵袭[1]。 HDAC-IN-57 (1.0 μM,2.5 μM,5.0 μΜ;48小时) 显著抑制实体肿瘤细胞系 MGC-803,A549,HCT-116 的生长,IC50s 值分别为 0.45 μM, 1.48 μM 和 0.57 μM[1]。 HDAC-IN-57 (1.0 μM,2.5 μM,5.0 μΜ;48小时) 以剂量依赖性方式触发 MGC-803 和 HCT-116 细胞凋亡[1]。 HDAC-IN-57 (1.0 μM,2.5 μM,5.0 μΜ;48小时) 抑制 MGC-803 和 HCT-116 细胞系内 LSD1 和 HDACs[1]。 HDAC-IN-57 (1.0 μM,2.5 μM,5.0 μΜ;48小时) 诱导 MGC-803 和 HCT-116 细胞周期 G2/M 期阻滞[1]。 HDAC-IN-57 在体外代谢稳定性高。在人肝脏 (HLM) 和大鼠肝脏微粒体 (RLM) 中孵育1 小时后分别保持母体化合物的 86.1% 和 87.4%,T1/2超过 120 分钟[1]。 Western Blot Analysis[1] Cell Line: MGC-803 cells, HCT-116 cells Concentration: 1.5 μM Incubation Time: 48 hours Result: Inhibited cellular LSD1 and HDACs. Upregulated the expression of apoptotic markers, including cytochrome C, Bax, cleaved caspase-3/7/9, and cleaved PARP, while downregulating the expression of anti-apoptotic protein Bcl-2. Apoptosis Analysis[1] Cell Line: MGC-803 cells, HCT-116 cells Concentration: 1.0 μM, 2.5 μM, 5.0 μM Incubation Time: 48 hours Result: Triggered MGC-803 and HCT116 cells apoptosis in a dose-dependent manner. Induced about 55.4% and 51.5% MGC-803 cell apoptosis at a concentration of 5 μM. Cell Migration Assay [1] Cell Line: MGC-803 cells, HCT-116 cells Concentration: 1.0 μM, 2.0 μM, 4 μM Incubation Time: 48 hours Result: Reduced the number of migrated of MGC-803 and HCT-116 cells. Inhibited the migration and invasion of cancer cells. Cell Cycle Analysis[1] Cell Line: MGC-803 cells, HCT-116 cells Concentration: 1.0 μM, 2.5 μM, 5.0 μM Incubation Time: 48 hours Result: Induced G2/M cycle arrest in MGC-803 and HCT-116 cells. |
In Vivo | HDAC-IN-57 (Compound 5e) (静脉注射1 mg/kg,口服10 mg/kg) 显示 T<sub>1/2HDAC-IN-57 (25或50 mg/kg灌胃;每天1次,连续21天) 在 NOD-SCID 小鼠 MGC-803 异种移植模型中实现了剂量依赖性肿瘤生长抑制[1]。 Animal Model: MGC-803 xenograft model in NOD-SCID mice[1] Dosage: 25 or 50 mg/ kg Administration: Oral gavage (p.o.); Result: Achieved a dose-dependent tumor growth inhibition (TGI) of 44.8% at 25 mg/kg and 71.5% at 50 mg/kg. Animal Model: Male SD rats (Pharmacokinetic assay)[1] Dosage: 1 mg/kg; 10 mg/kg Administration: Intravenous injection (i.v.); Oral gavage (p.o.) Result: Pharmacokinetic parameters for HDAC-IN-57 (Compound 5e) in SD rats[1] Route Dose (mg/kg) T1/2 (h) Tmax (h) CL (mL•min-1/kg-1) AUC0-t (h•ng/mL) AUC0-Ꝏ (h•ng/mL) Cmax (ng/mL) VZ (L/kg) F (%) i.v. 1 0.37 / 1.61 644.1 645.8 1892.8 0.82 / p.o. 10 2.75 0.25 / 685.2 766.2 716.4 52.2 10.6 分子量 377.39 Formula C21H19N3O4 CAS 号 2716217-79-5 运输条件 Room temperature in continental US; may vary elsewhere. 储存方式 Please store the product under the recommended conditions in the Certificate of Analysis. 纯度 & 产品资料 Data Sheet (535 KB) 产品使用指南 (1538 KB) 参考文献 [1]. Duan Y, et al. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem. 2023 Jun 5;254:115367. [Content Brief] [1]. Duan Y, et al. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem. 2023 Jun 5;254:115367. Help & FAQs Do most proteins show cross-species activity? Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species. 摩尔计算器 稀释计算器 The molarity calculator equation Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) 质量 浓度 体积 分子量 * kg g mg μg ng pg = M mM μM nM pM × L mL μL × The dilution calculator equation Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final) M mM μM nM pM × L mL μL = M mM μM nM pM × L mL μL C1 V1 C2 V2 Powered by Bioz See more details on Bioz Keywords: HDAC-IN-572716217-79-5HDACApoptosisHistone deacetylasesHDAC1 inhibitoranti-tumorMGC-803HCT-116xenograft modelsInhibitorinhibitorinhibit 您最近查看的产品: Your information is safe with us. * Required Fields. 产品名称: * 需求量: mg g kg t mL L * 客户姓名: * Email: * 电话: * 公司或机构名称: 留言给我们: Bulk Inquiry Inquiry Information 产品名称: HDAC-IN-57 目录号: HY-149946 需求量: Request for HNMR Report Please fill out this form to request the QC report. We will send it to your Email address shortly. Your information is safe with us. * Required Fields. 产品名称: * Lot #: * 客户姓名: * Email: 电话: * 部门: * 公司或机构名称: 留言给我们: Request for HNMR Report We have received your request and will respond to you as soon as possible. sales@MedChemExpress.cn 400-820-3792 联系当地授权经销商 MCE 公司 联系我们 关于我们 全球办事处 许可 职业发展 服务与支持 技术支持 定制合成服务 订购指南 售后服务 物流政策 销售条款和条件 技术资源 学术文献 摩尔计算器 稀释计算器 复溶计算器 比活力计算器 Subscribe to our E-newsletter 姓名 邮箱 * Sorry, but the email address you supplied was invalid. Thanks, your subscription has been confirmed. You will hear from us soon. Submission failed, please try again later. MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。 站点地图 隐私声明 Copyright © 2013-2023 MedChemExpress. All Rights Reserved. 沪ICP备15051369号-4 关注我们 获得 MCE 最新资讯 您的账户在别处登录,如果非您本人行为 请重置密码! 我们的 Cookie 政策 我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》。 |
References |
Molecular Formula | C21H19N3O4 |
---|---|
Molecular Weight | 377.39 |